Protective Effects of Oral L-Arginine Supplement in Patients With CKD After Intravenous Contrast Media Injection
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 112
- 试验地点
- 2
- 主要终点
- Incidence of Contrast-induced acute kidney injury (CI-AKI)
研究概览
简要总结
This trial was performed to examine the efficacy of oral L-arginine for preventing CI-AKI in chronic kidney disease (CKD) patients.
详细描述
Contrast-induced acute kidney injury (CI-AKI) is a common complication in hospitalized patients. Nitric oxide-signal transduction plays an important role in prevention of CI-AKI. L-Arginine is an amino acid involved in ammonia detoxification, and is well known as a precursor to nitric oxide, a key component of endothelial-derived relaxing factor.
This is a prospective randomized, double blind, placebo controlled trial among CKD stage 3-4 patients undergoing computer tomography. Eligible patients were randomly assigned to two groups: (1) arginine 3 g/day or 6 capsules per day, and (2) placebo 6 capsules per day for 3 days before contrast media injection. Serum cystatin C, serum creatinine and estimated GFR was measured at baseline and 48 hours after procedure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age ≥ 18 years
- •Stable CKD stage 3-4 patients
- •Patients undergoing elective contrast media injection
排除标准
- •History of arginine allergy
- •Acute kidney injury diagnosed within 4 weeks
- •Active infection/sepsis
- •Severe liver disease
结局指标
主要结局
Incidence of Contrast-induced acute kidney injury (CI-AKI)
时间窗: 48 hours
次要结局
- Number of Adverse effects(48 hours)